Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
Evolus’ Jeuveau (DWP-450) (prabotulinumtoxinA) will likely prove to be a strong competitor to Allergan’s Botox (botulinum toxin type...
Evolus’ Jeuveau (DWP-450) (prabotulinumtoxinA) will likely prove to be a strong competitor to Allergan’s Botox (botulinum toxin type...
Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into...
In late December, Merck and Sanofi secured FDA approval for Vaxelis (diphtheria, tetanus, and acellular...
US Senator Bernie Sanders and Representative Elijah Cummings have announced plans to introduce three new...
National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine...
Pharmaceutical company Bristol-Myers Squibb has bought US biotech Celgene for $74bn as it seeks to...
China’s CANbridge Pharmaceuticals has expanded its alliance with WuXi Biologics for the discovery, development and...
With an ageing population, more people than ever are relying on carers, be it professionals...
Allakos’s Phase IIa AK002 trial in chronic spontaneous urticaria had challenging enrolment criteria, two investigators...
As the US increases the state-approved production and supply of cannabis-derived pharmaceutical products, there are...